Anticoagulant effects of edoxaban in cancer and noncancer patients with venous thromboembolism
{{output}}
Background: Edoxaban, a direct oral anticoagulant (DOAC), is a first-line treatment for venous thromboembolism (VTE) and the suppression of VTE recurrence. In patients with cancer, however, recurrent VTE after DOAC treatment may ... ...
